Muss H B, Bundy B N, Given F T, Stehman F B
Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina.
Am J Clin Oncol. 1990 Apr;13(2):117-8. doi: 10.1097/00000421-199004000-00006.
Twenty-three evaluable patients with non-squamous-cell carcinoma of the cervix were treated with teniposide 100 mg/m2 per week administered as a 30-60 min infusion. Escalations of 20 mg/m2 per week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Thirteen of the 23 patients had no prior chemotherapy. One patient had a partial response (95% confidence intervals for response less than or equal to 19%). Toxicity was minimal. Seven patients had white blood cell counts of less than 2,000/mm3 but only one had less than 1,000/mm3. No patients had platelet counts less than 50,000/mm3, and no bleeding or septic episodes were noted. Two patients had mild nausea and seven had mild nausea and vomiting. Teniposide displays no major activity in patients with non-squamous-cell cervical cancer.
23例可评估的宫颈非鳞状细胞癌患者接受了替尼泊苷治疗，剂量为每周100mg/m²，静脉输注30 - 60分钟。对未出现毒性反应的患者，每周剂量递增20mg/m²，最大剂量为160mg/m²。23例患者中有13例未曾接受过化疗。1例患者出现部分缓解（缓解率的95%置信区间小于或等于19%）。毒性反应轻微。7例患者白细胞计数低于2000/mm³，但只有1例低于1000/mm³。没有患者血小板计数低于50000/mm³，也未观察到出血或感染事件。2例患者有轻度恶心，7例患者有轻度恶心和呕吐。替尼泊苷在宫颈非鳞状细胞癌患者中未显示出主要活性。
